Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients

International Journal of Laboratory Hematology

Volumn 32, Issue 1 PART.2, 2010, Pages 103-112

  Ghaith, F ^a   Abdou, S ^a   El Bendary, A ^a   Shahin, D ^b   Eid, M ^a   Megeed, W A ^c   El Sheikh, I ^a   Farrag, W ^a   Yousuf, S ^d  

^a TANTA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c Tanta Oncology Centre   (Egypt)

^d AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

9q34; CML; FISH; PCR; SOCS

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; PARACETAMOL; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ARTICLE; CHILL; CHROMOSOME 9Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE TITRATION; EVENING DOSAGE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REPRESSION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SPLENOMEGALY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHROMOSOME DELETION; DISEASE-FREE SURVIVAL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 77449099047     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2009.01143.x     Document Type: Article

References (29)

1. Alexander W.S., Starr R., Metcalf D., Nicholson S.E., Farley A., Elefanty A.G., Brysha M., Kile B.T., Richardson R., Baca M., Zhang J.G., Willson T.A., Viney E.M., Sprigg N.S., Rakar S., Corbin J., Mifsud S., DiRago L., Cary D., Nicola N.A. & Hilton D.J. (1999) Suppressors of cytokine signaling(SOCS): Negative regulators of signal transduction. Journal of Leukocyte Biology 66, 588-592.
2. Aoun P., Wiggins M., Rasheed H., Pickering D., Foran J., Rasheed H., Pavletic S.Z. & Sanger W. (2004) Interphase Fluorescence in situ hybridization studies for the detection of 9q34 deletions in CML. Cancer Genetics and Cytogenetics 154, 138-143.
3. Bacher U., Schnittger S., Kern W., Hiddemann W., Haferlach T. & Schoch C. (2005) The incidence of sub microscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica 90, 558-559.
4. Bain B.J. (2003) Chronic myeloid leukaemias. In: Leukaemia diagnosis, 180-184. Blackwell Science, Oxford, UK.
5. Costa D., Carrio A., Madrigal I., Arias A., Valera A., Colomer D. & Aguilar J.L. (2006) Studies of complex ph translocations in cases with chronic myeloid leukemia. Cancer Genetics and Cytogenetics 166, 89-93.
6. Daly G.Q., Van Etten R.A. & Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the p210 bcr/ abl gene of Ph. Chromosome Science 247, 824-830.
7. Fournier M., Lacrosse S., Jamar M. & Bours V. (2005) Deletions of the 30BCR and S'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: A one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells. Cancer Genetics and Cytogenetics 160, 184-187.
8. Huntly B.J.P., Bench A. & Green A.R. (2003a) Deletion of a derivative chromosome 9 in chronic myeloid leukemia. Blood 102, 1160-1168.
9. Huntly B.J.P., Reid A.G., Bench A.J., Campbell L.J., Nick Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P. & Green A.R. (2001) Deletions of the derivative chromosome 9 occur at the time of ph translocation and provide powerful and independent prognostic indicator in CML. Blood 98, 1732-1738.
10. Huntly B.J.P., Bench A.J., Delabesse E., Reid A.G., Li J., Scott M.A., Campbell L., Byrne J., Pinto E., Brizard A., Niedermeiser D., Nacheva E.P., Guilhot F., Deininger M. & Green A.R. (2002) Derivative chromosome 9 deletions in chronic myeloid leukemia: Poor prognosis is not associated with loss of ABL/ BCR expression, elevated BCR/ABL levels, or karyotypic instability. Blood 99, 4547-4553.
11. Huntly B.J.P., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Nick Bown., Clark R.E., Nacheva N.P., Green A.R. & Deininger M.W.N. (2003b) Imatinib improves but may not fully reverse the poor prognosis of patients with CML derivative chromosome 9 deletions. Blood 102, 2205-2217.
12. Kantarjian H.M., Keating M.J., Talpaz M., Walters R.S., Smith T.L., Cork A., McCredie K.B. & Freireich E.J. (1987) Chronic myelogenous leukemia in blastic crisis: Analysis of 242 patients. American Journal of Medicine 83, 445-454. (Pubitemid 18109903)
13. Kantarjian H.M., Dixon D., Keating M.J., Talpaz M., Walters R.S., McCredie K.B. & Freireich E.J. (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61, 1441-1446. (Pubitemid 18076421)
14. Kantarjian H.M., O'Brien S., Anderlini P. & Talpaz M. (1996) Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87, 3069-3081.
15. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J. & Squire J.A. (2001) Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97, 3581.
16. Lee Y.K., Kim Y.R., Min H.C., Oh B.R., Kim T.Y., Kim Y.S., Cho H.I., Kim H.C., Lee Y.S. & Lee D.S. (2006) Deletion of any part of the BCR or ABL gene on the derivative Ch. 9 is a poor prognostic marker in chronic myeloid leukemia. Cancer Genetics and Cytogenetics 166, 65-73.
17. Lim T.H., Tien S.L. & Lim A.S. (2005) The incidence and pattern of BCR/ABL rearrangements in chronic myeloid leukemia using fluorescence in situ hybridization. Annals of the Academy of Medicine, Singapore 34, 533-538.
18. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., Akira S. & Kishimoto T. (1997) Structure and function of a new STATinduced STAT inhibitor. Nature 387, 924-929.
19. Reid G.A., Huntly B.J.P., Green A.R. & Nacheva E.P. (2003) Survival implications of molecular heterogeneity in variant Ph-positive CML. British Journal of Hematology 121, 419-427.
20. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Cervantes F., Barrios M., Colomer D., Heiniger A. & Torres A. (2004) the suppressor of cytokine a signaling-1 is constitutively expressed in chronic myeloid leukaemia and correlates with poor cytogenetic response to interferon α. Haematologica 89, 42-48.
21. Sakai I., Takeuchi K., Yamauchi H. & Fujita S. (2002) Constitutive expression of SOCS-3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood 100, 2926-2931.
22. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B. & Green A.R. (2000) Large deletions at the t (q22) break point are common and may identify a poor prognosis. Subgroup of patients with chronic myeloid leukemia. Blood 95, 738-743.
23. Song M.M. & Shuai K. (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. The Journal of Biological Chemistry 273, 35056-35062.
24. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R. & Jenkins B.J. (1997) A family of cytokine-inducible inhibitors of signaling. Nature 387, 917-921.
25. Starr R., Metcalf D., Elefanty A.G., Brysha M., Willson T.A., Nicola N.A., Hilton D.J. & Alexander W.S. (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proceedings of the National Academy of Sciences of the United States of America 95, 14395-14399.
26. Talpaz M., McCredie K., Kantarjian H., Trujillo J., Keating M. & Gutterman J. (1986a) Chronic myelogenous leukaemia: haematological remissions with alpha interferon. British Journal Haematology 64, 87-95.
27. Talpaz M., Kantarjian H.M., McCredie K., Trujillo J.M., Keating M.J. & Gutterman J.U. (1986b) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New England Journal of Medicine 314, 1065-1069.
28. Talpaz M., Kantarjian H., Kuruzrock R., Trujilo J.M. & Guttermann J.U. (1991) Interferon-alpha produces sustained cytogenetic response in chronic myeloid leukemia. Annals of Internal Medicine 114, 532-538.
29. Yang H.p., Dai M., Zhou H.S., Huang L. & Zhang D.H. (2006) Detection of SCOS-1 mRNA expression by RT-PCR in the patients with myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi Aug 14, 677-680.